Wechselwirkungen von Icosapent-Ethyl
Icosapent-Ethyl (Vascepa), ein Omega-3-Fettsäuren-Präparat, hat in den von uns erfassten FDA-Fachinformationen und Faktenblättern 33 dokumentierte Wechselwirkungen: 0 schwerwiegende, 33 mittelschwere, 0 geringfügige und 0, bei denen eine Fachinformation keine relevante Wechselwirkung berichtet. Jeder Eintrag unten zitiert den Satz, auf dem er beruht. Diese Medikamentenseite ist ein Ausgangspunkt, kein Urteil über Ihre persönliche Situation.
Wechselwirkungen laut Fachinformation
Mittelschwere Wechselwirkungen (33)
The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin. (Fachinformation zu Icosapent-Ethyl, Warnhinweise und Vorsichtsmaßnahmen)
The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin. (Fachinformation zu Icosapent-Ethyl, Warnhinweise und Vorsichtsmaßnahmen)
In a double-blind, placebo-controlled trial of 8,179 statin-treated subjects with established cardiovascular disease (CVD) or diabetes plus an additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 or more hours occurred in 127 (3%) patients treated with VASCEPA compared to 84 (2%) patients receiving… (Fachinformation zu Icosapent-Ethyl, Warnhinweise und Vorsichtsmaßnahmen)
Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (Fachinformation zu Icosapent-Ethyl, Arzneimittelwechselwirkungen)
Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (Fachinformation zu Icosapent-Ethyl, Arzneimittelwechselwirkungen)
In a double-blind, placebo-controlled trial of 8,179 statin-treated subjects with established cardiovascular disease (CVD) or diabetes plus an additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 or more hours occurred in 127 (3%) patients treated with VASCEPA compared to 84 (2%) patients receiving… (Fachinformation zu Icosapent-Ethyl, Warnhinweise und Vorsichtsmaßnahmen)
Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (Fachinformation zu Icosapent-Ethyl, Arzneimittelwechselwirkungen)
The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin. (Fachinformation zu Icosapent-Ethyl, Warnhinweise und Vorsichtsmaßnahmen)
The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin. (Fachinformation zu Icosapent-Ethyl, Warnhinweise und Vorsichtsmaßnahmen)
Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (Fachinformation zu Icosapent-Ethyl, Arzneimittelwechselwirkungen)
Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (Fachinformation zu Icosapent-Ethyl, Arzneimittelwechselwirkungen)
The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin. (Fachinformation zu Icosapent-Ethyl, Warnhinweise und Vorsichtsmaßnahmen)
Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (Fachinformation zu Icosapent-Ethyl, Arzneimittelwechselwirkungen)
Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (Fachinformation zu Icosapent-Ethyl, Arzneimittelwechselwirkungen)
Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (Fachinformation zu Icosapent-Ethyl, Arzneimittelwechselwirkungen)
Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (Fachinformation zu Icosapent-Ethyl, Arzneimittelwechselwirkungen)
Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (Fachinformation zu Icosapent-Ethyl, Arzneimittelwechselwirkungen)
In a double-blind, placebo-controlled trial of 8,179 statin-treated subjects with established cardiovascular disease (CVD) or diabetes plus an additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 or more hours occurred in 127 (3%) patients treated with VASCEPA compared to 84 (2%) patients receiving… (Fachinformation zu Icosapent-Ethyl, Warnhinweise und Vorsichtsmaßnahmen)
Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (Fachinformation zu Icosapent-Ethyl, Arzneimittelwechselwirkungen)
In a double-blind, placebo-controlled trial of 8,179 statin-treated subjects with established cardiovascular disease (CVD) or diabetes plus an additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 or more hours occurred in 127 (3%) patients treated with VASCEPA compared to 84 (2%) patients receiving… (Fachinformation zu Icosapent-Ethyl, Warnhinweise und Vorsichtsmaßnahmen)
Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (Fachinformation zu Icosapent-Ethyl, Arzneimittelwechselwirkungen)
Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (Fachinformation zu Icosapent-Ethyl, Arzneimittelwechselwirkungen)
In a double-blind, placebo-controlled trial of 8,179 statin-treated subjects with established cardiovascular disease (CVD) or diabetes plus an additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 or more hours occurred in 127 (3%) patients treated with VASCEPA compared to 84 (2%) patients receiving… (Fachinformation zu Icosapent-Ethyl, Warnhinweise und Vorsichtsmaßnahmen)
The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin. (Fachinformation zu Icosapent-Ethyl, Warnhinweise und Vorsichtsmaßnahmen)
In a double-blind, placebo-controlled trial of 8,179 statin-treated subjects with established cardiovascular disease (CVD) or diabetes plus an additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 or more hours occurred in 127 (3%) patients treated with VASCEPA compared to 84 (2%) patients receiving… (Fachinformation zu Icosapent-Ethyl, Warnhinweise und Vorsichtsmaßnahmen)
Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (Fachinformation zu Icosapent-Ethyl, Arzneimittelwechselwirkungen)
In a double-blind, placebo-controlled trial of 8,179 statin-treated subjects with established cardiovascular disease (CVD) or diabetes plus an additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 or more hours occurred in 127 (3%) patients treated with VASCEPA compared to 84 (2%) patients receiving… (Fachinformation zu Icosapent-Ethyl, Warnhinweise und Vorsichtsmaßnahmen)
Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (Fachinformation zu Icosapent-Ethyl, Arzneimittelwechselwirkungen)
In a double-blind, placebo-controlled trial of 8,179 statin-treated subjects with established cardiovascular disease (CVD) or diabetes plus an additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 or more hours occurred in 127 (3%) patients treated with VASCEPA compared to 84 (2%) patients receiving… (Fachinformation zu Icosapent-Ethyl, Warnhinweise und Vorsichtsmaßnahmen)
In a double-blind, placebo-controlled trial of 8,179 statin-treated subjects with established cardiovascular disease (CVD) or diabetes plus an additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 or more hours occurred in 127 (3%) patients treated with VASCEPA compared to 84 (2%) patients receiving… (Fachinformation zu Icosapent-Ethyl, Warnhinweise und Vorsichtsmaßnahmen)
Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (Fachinformation zu Icosapent-Ethyl, Arzneimittelwechselwirkungen)
Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (Fachinformation zu Icosapent-Ethyl, Arzneimittelwechselwirkungen)
The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin. (Fachinformation zu Icosapent-Ethyl, Warnhinweise und Vorsichtsmaßnahmen)
Prüfen Sie Icosapent-Ethyl gegen alles, was Sie einnehmen. Fügen Sie Ihre gesamte Liste hinzu; alle Paare werden auf einmal geprüft.
Im Wechselwirkungscheck öffnenKeine medizinische Beratung. Der Schweregrad gibt die Formulierung der Fachinformation wieder, nicht Ihre persönlichen Umstände. Eine als „schwerwiegend“ eingestufte Wechselwirkung kann unter Aufsicht Routine sein, und eine „geringfügige“ kann bei hohen Dosen von Bedeutung sein. Fragen Sie in einer Apotheke nach.